#USA #Washington, D.C. #GLP-1 #Milken Institute #pharmacies

A Critical Resource for GLP-1 Patients

In a recently released report by the Milken Institute, the emphasis is placed on the essential role that pharmacies play in the ongoing success of patients using GLP-1 medications. For many Americans, simply filling a prescription is the initial step in a much longer journey toward better health, characterized by sustained management of their condition challenges. This report, unveiled during the Milken Institute's Future of Health Summit in Washington, D.C., articulates key strategies to elevate the support offered by neighborhood pharmacies and highlights the urgent need for solutions that facilitate consistent care beyond mere prescriptions.

Pharmacies have emerged as a frontline resource, not only filling prescriptions but also aiding in the navigation of medication regimes. It's noted that for chronic conditions like obesity and related cardiometabolic disorders, support must extend beyond single interventions. Therefore, the report suggests a comprehensive approach where pharmacies act as trusted partners throughout the GLP-1 care process, from side-effect management to adherence encouragement.

Recommendations for Key Stakeholders

The new findings lay out specific recommendations for various stakeholders in the healthcare landscape:

• - Policymakers: The report urges legislative action to enable coverage for pharmacist-provided services related to GLP-1 medications, emphasizing the need for reimbursement pathways for vital support services including counseling and medication management. Moreover, assessing existing Medicare and Medicaid coverage is essential to expand access to these treatments.
• - Pharmacies: The report encourages pharmacies to establish a standardized list of GLP-1 services, enhancing consistency in the types of assistance offered across locations.
• - Prescribers: It's important for healthcare providers to resolve any coverage issues before patients reach their pharmacy, thereby ensuring they have the necessary access to medications and support.
• - Payers: Health insurance providers are prompted to incorporate pharmacy-based support services into their coverage programs and use data to better understand how patients are adhering to their treatment plans.
• - Patients: Patients are encouraged to engage openly with their pharmacists about side effects and essential lifestyle adjustments, including dietary changes.

The research highlights that patients are more likely to succeed with their GLP-1 treatments when they possess increased access to their pharmacists. The NACDS President and CEO, Steven C. Anderson, articulated this sentiment, stressing that a prescription should not be seen as a finisher but rather the beginning of a collaborative healthcare journey. Through consistent pharmacy engagement, patients can enhance the likelihood of achieving positive health outcomes.

The Trust Factor

The data suggests an overwhelming trust among patients toward pharmacists, with recent surveys indicating that 83% of adults and 93% of GLP-1 medication users view pharmacists as reliable sources for addressing their questions. This trust runs parallel to their confidence in physicians, which stands at 97%, indicating that they see pharmacists not only as providers of medication but as vital healthcare partners.

When asked about the value of pharmacists' services, a significant number of GLP-1 users identified that assistance with navigating coverage issues, addressing side effects, and clarifying medication usage were most critical. Furthermore, many expressed the need for resources related to lifestyle adjustments, such as physical activity guides and dietary consultations.

Conclusion

Pharmacies are in a prime position to bridge gaps in healthcare delivery, particularly for patients utilizing GLP-1 medications. As highlighted by Athena Rae Roesler, director at the Milken Institute, pharmacists represent accessible, trusted, and integral components in patient care. The challenge ahead is to reinforce this role through improved infrastructure, reimbursement strategies, and collaborative efforts among stakeholders across the healthcare sector. As more patients seek help through GLP-1 treatments, the role of the pharmacist will undoubtedly become pivotal in fostering ongoing success and improving health standards across the nation.

For those interested, the full report titled Beyond the Prescription: Community Pharmacy's Role in Comprehensive GLP-1 Care is available through the Milken Institute’s website.